CURRICULUM VITAE
`
`Jan nary 2017
`
`Lewis J. Rubin, MD, FACP, FCCP, FAHA, FRCP
`
`Emeritus Professor of Medicine
`
`Emeritus Director, Pulmonary and Critical Care Division
`University of California, San Diego School of Medicine
`
`Adjunct Professor of Medicine
`Columbia University College of Physicians and Surgeons, New York, NY
`
`HOME OFFICE:
`
`690 Orchard Shore Road
`Colchester, VT 05446
`Tel: 802-891-9094; Fax: 858-736-2423
`E-mail: 1jr@1ewisrubinmd.com
`
`BIRTHDATE:
`
`August 5, 1950. New York, New York
`
`EDUCATION:
`
`1963 — 1972
`
`BA.
`
`Yeshiva University
`New York, New York
`
`1968 — 1972
`
`Yeshiva University
`Diploma in
`Hebraic Studies New York, New York
`
`1972 — 1975
`
`MD.
`
`Albert Einstein College of Medicine
`Bronx, New York
`
`Internship:
`1975 ~ 19?6
`
`Residency:
`1976 _ 197’?
`
`1978
`
`Fellowship:
`
`1978 e 1979
`
`Duke University Medical Center
`Durham, North Carolina
`
`Jr. Assistant Resident in Medicine
`Duke University Medical Center
`Durham, North Carolina
`
`Sr. Assistant Resident in Medicine
`Assistant Chief Medical Resident
`
`Duke University Medical Center
`Durham, North Carolina
`
`Fellow in Allergy and Respiratory Diseases
`Duke University Medical Center
`Durham, North Carolina
`
`UNITED THERAPEUTICS, EX. 2023
`WATSON LABORATORIES V. UNITED THERAPEUTICS, |PR2017—D1621
`Page 1 of 62
`
`

`

`CERTIFICATIONS:
`
`I976
`I978
`I980
`1989
`
`LICENSURE:
`I978
`1981
`1985
`1999
`2015
`
`RESEARCH
`INTERESTS:
`
`FACULTY POSITIONS:
`
`2016 —
`
`2010 — present
`
`Diplomate, National Board ofMedica] Examiners
`Diplomale, American Board oflnternal Medicine
`Subspecialty Boards in Pulmonary Disease
`Subspeeialty Boards in Critical Care
`
`North Carolina (active)
`Texas (inactive)
`Maryland (active)
`California (active)
`New York (active)
`
`The Pulmonary Circulation
`Pulmonary Physiology
`Cardiopulmonary Interrelationships
`
`Adjunct Professor of Medicine
`Columbia University College of Physicians and Surgeons, New York
`
`Emeritus Professor of Medicine
`University of California, San Diego School ofMedicine
`
`1999 — 2010
`
`Professor ofMedicinc
`
`1999 — 2002
`
`1985 — 1993
`
`University of California, San Diego School ofMedicinc
`
`Director, Division ofPulmonary and Critical Care Medicine
`University ofCalifornia, San Diego School of Medicine
`
`Head, Division of Pulmonary and Critical Care Medicine
`University ofMaryland School of Medicine
`
`1990 — 1998
`
`Professor of Medicine
`
`1990 — I998
`
`1986 — 1990
`
`University of Maryland School ofMedicinc
`
`Professor of Physiology
`University of Maryland School ofMedicinc
`
`Associate Professor of Physiology
`University of Maryland School of Medicine
`
`1985 -— 1990
`
`Associate Professor of Medicine
`
`1984 — 1985
`
`University of Maryland School ofMedicinc
`
`Associate Professor of Internal Medicine
`University ofTexas Health Science Center at Dallas
`Southwestern Medical School
`
`UNITED THERAPEUTICS, EX. 2023
`WATSON LABORATORIES V. UNITED THERAPEUTICS, |PR2017—D1621
`Page 2 of 62
`
`

`

`198l—l984
`
`Assistant Professor oflnlernal Medicine
`
`University of'l‘exas Health Science Center at Dallas
`Southwestern Medical School
`
`1979—1980
`
`Associate, Department of Medicine
`Duke University Medical Center
`
`MAJOR ACADEMIC TASKS:
`
`l999~2002
`
`1985— 1998
`
`1981—1985
`
`Director, Division of Pulmonary and Critical Care Medicine
`University of‘California, San Diego School of Medicine, San Diego,
`California
`
`Ilead, Pulmonary and Critical Care DivisiOn
`University of Maryland School of Medicine, Baltimore, Maryland
`
`Chief, Pulmonary Section, VA. Medical Center, Dallas, Texas
`
`PROFESSIONAL MEMBERSHIPS:
`
`HONORS AND AWARDS:
`
`American College ot‘Chest Physicians (Fellow)
`American College ofPhysicians (Fellow)
`American Heart Association, Cardiopulmonary Council (Fellow)
`American Society for Clinical Investigation (elected 1995)
`American Thoracic Society
`lnterurban Clinical Club (elected 1996)
`California Thoracic Society
`International Society for Heart and Lung Transplantation
`North Carolina Commission on Occupational Lung Diseases
`Alpha Epsilon Delta (Premedical Honor Society)
`The LAM Foundation, Clinical Trials Advisory Board
`
`B.A., Cum Laude, 1972
`New York State Regents Scholarship, 19684972
`Yeshiva University Academic Scholarship, 1968—1972
`I-laskel Schifwaard in Clinical Medicine, Duke University Medical
`Center, 1978
`Edward Livingston Trudeau Fellow, American Lung Association,
`1980-8]
`
`Listed in Who's Who in Frentier Science and Technology, 1983
`Listed in Who’s Who in Science and Engineering, 201 1—12; 2016—”
`
`Listed in Who’s Who in Medicine and llealthcare, 2009—2012
`
`Listed in Who’s Who in America, 2004—20l6
`Listed in Who’s Who in the World, 2005, 2009—2016
`Listed in Best Doctors in America, l994—2014
`
`Listed in America’sTop Doctors, 2005—20] ]
`
`UNITED THERAPEUTICS, EX. 2023
`WATSON LABORATORIES V. UNITED THERAPEUTICS, |PR2017—D1621
`Page 3 of 62
`
`

`

`Scientific Progress Award, Primary Pulmonary Hypertension Cure
`Foundation, 1997
`Dickinson W. Richards Memorial Lecturer, American Heart
`Association, 1997
`George Comstock, MD. Award, American Lung Association of
`Maryland, 1997
`Faculty Research Lecturer ofthc Year, University of Maryland
`Founders Day Celebration, 1998
`Kenneth Moser Memorial Award, Pulmonary I lypertension
`Association, I998
`Visiting Professor & Visiting Scientist, Wolfson Institute for
`Biomedical Research and University College London, United
`Kingdom, I999
`Honorary Fellow, Royal College of Physicians, United Kingdom,
`2002
`
`Scientific Achievement Award, Polish Society of Cardiology, 2006
`Honorary Fellow, Venezuelan Society of Cardiology, 2009
`Simon Dack Award for Outstanding Scholarship, American College
`ofCardiology, 20l2
`Most Influential Researchers in the World, Thomas Reuters, 2014 and
`2015
`
`Lifetime Achievement Award, Pulmonary Vascular Research
`Institute (PVRI), 2016
`CHEST College Medalist Award, American College of Chest
`Physicians, 2M6
`
`EDITORIAL TASKSMANUSCRIPT REVIEWER:
`
`Editorshipstditorial Boards:
`0
`Structural Heart: The Journal ofthc Heart Team
`
`0
`
`(Editorial Consultant 2017-2019)
`Journal ofthe American College ofCardiology
`(Senior Consulting Editor 2002—2014)
`0 Annals of Internal Medicine (Editorial Board 2005—
`2009}
`a American Journal of Respiratory and Critical Care
`Medicine (Editorial Board 2003—2006))
`0 Respiratory Research (Associate Editor)
`0 Clinical Pulmonary Medicine (Associate Editor)
`0
`Journal ofIleart and Lung 'l‘ransplantation (Editorial
`Board)
`
`Manuscript Reviewer:
`
`Science
`
`0....
`
`New England Journal of Medicine
`Lancet
`
`Journal ofthe American Medical Association (JAMA)
`
`Journal ofCIinical Investigation
`
`UNITED THERAPEUTICS, EX. 2023
`WATSON LABORATORIES V. UNITED THERAPEUTICS, |PR2017—D1621
`Page 4 of 62
`
`

`

`Circulation
`Circulation Research
`
`American Journal of Physiology
`Chest
`
`Journal oprplied Physiology
`American Journal ofCardiology
`American Journal of Respiratory Cell and Molecular
`Biology
`Intensive Care Medicine
`Critical Care Medicine
`
`Journal of Respiratory Diseases
`Pediatric Pulmonology
`Kidney International
`The Western Journal oi‘Medicine
`American Journal of Medicine
`American Journal ofMedicaI Sciences
`
`Respiratory Medicine
`Journal of Rheumatology
`Mayo Clinic Proceedings
`American Journal of Pathology
`European Respiratory Journal
`European Heart Journal
`Pediatrics
`
`Clinical Pharmacokinetics
`Annals of Rheumatic Diseases
`
`Journal of Pharmacology and Experimental
`'l‘herapcutics
`Pediatric Research
`Journal of’I‘hrombosis and Haemostasis
`FASEB Journal
`
`Arteriosclerosis, Thrombosis, and Vascular Biology
`'l‘horax
`
`Drugs
`Journal of Molecular Medicine
`
`Avian Pathology
`Cardiology
`Computational & Mathematical Methods in Medicine
`Science ’l'ranslational Medicine
`Cell Metabolism
`
`MAJOR CON SU LTA NTSI II PS:
`
`1983
`
`1985 — 1992
`
`Occupational Lung Disease, United States Justice Department
`
`American Medical Association, Division of Drugs and
`Technology
`
`UI
`
`UNITED THERAPEUTICS, EX. 2023
`WATSON LABORATORIES V. UNITED THERAPEUTICS, IPR2017—D1621
`Page 5 of 62
`
`

`

`[99I — I993
`
`Rand Corporation, Santa Monica, California
`
`|99l — [992
`
`World Ilealth Organization (WHO)
`
`1993 -
`
`[995
`
`I997 -— 2002
`
`I997 —
`
`1997' —— [998
`
`I998 ~ 200]
`
`1998 —
`
`1999
`
`2002 —
`
`2006
`
`2002 —
`
`2005 ~
`
`2005 —
`
`2006 —
`
`International Primary Pulmonary Hypertension (IPPil) Study
`Diagnosis Committee
`
`Steering Committee, Study of Pulmonary I Iypertension in
`America (SOPHIA) (through Harvard University School of
`Public Health)
`
`Coordinating Committee, International Registry ofPrimary
`Pulmonary Hypertension
`
`Steering Committee, Glaxo Welcome, Epoprostenol in
`Scleroderma-Induccd Pulmonary Ilypertension Study
`
`Chair, Steering Committee, United Therapeutics Corporation,
`l5-UT in Pulmonary Hypertension Study
`
`Advisory Committee, Schcring Pharmaceutics, Inhaled
`Iloprost in Pulmonary Hypertension Study
`
`Chair, Steering Committee, Actelion Pharmaceuticals,
`Bosentan in Pulmonary Hypertension Clinical Trials
`
`Advisory Committee, Pfizer Pharmaceuticals, Sildenafil in
`Pulmonary Hypertension Clinical Trials
`
`Chair, Steering Committee, Myogeni’GiIead Pharmaceuticals,
`Ambrisentan in Pulmonary Hypertension Clinical Trials
`
`Co-Chair, Steering Committee, Lunng, Inhaled 'Freprostinil
`Pulmonary Hypertension Clinical Program
`
`Chair, Pfizer Data Monitoring Committee (DMC) for
`sildenafil pediatric pulmonary hypertension trials
`
`Advisory Committee, MondoBioteeh, Inhaled Aviptadil in
`Pulmonary Hypertension Clinical Program
`
`External Reviewer, United Kingdom Medical Research
`Council
`
`2006 — 2008
`
`Scientific Advisory Board, Encysive Pharmaceuticals,
`Sitaxsentan in Pulmonary Hypertension Program
`
`2006 --
`
`Scientific Advisory Board, Aires Pharmaceuticals
`
`6
`
`UNITED THERAPEUTICS, EX. 2023
`WATSON LABORATORIES V. UNITED THERAPEUTICS, |PR2017—D1621
`Page 6 of 62
`
`

`

`200? — 2008
`
`2008 —- 2009
`
`2009 —20] 6
`
`2013 —
`
`CAMPUS ACTIVITIES:
`
`1985 — 1989
`
`1985 — 1997
`
`1986 — 1989
`
`1936 — 1998
`
`1990 — 1991
`
`1991 _ I993
`
`I991
`
`I998
`
`COMMITTEE ACTIVITIES:
`
`1981
`
`Member, Data and Safety Monitoring Board (DSMB) Gleevec
`pulmonary hypertension Phase 2 trial
`
`Scientific Advisory Board, Gilead Sciences, Inc.
`
`Scientific Advisory Board, United Therapeutics
`
`Special Government Employee {$613} to the Food and Drug
`Administration (FDA)
`
`Research and Development Committee, Baltimore VA.
`Medical Center Baltimore, Maryland
`
`Management Committee, University of Maryland School of
`Medicine, Department of Medicine, Baltimore, Maryland
`
`MDJPhD. Advisory Committee, University ot‘Maryland
`School of Medicine, Baltimore, Maryland
`
`Admissions Review Committee, University of Maryland
`School of Medicine, Baltimore, Maryland
`
`Radiology Chairman Search Committee, University of
`Maryland School of Medicine, Baltimore, Maryland
`
`Promotion and Tenure Appeals Committee, University of
`Maryland at Baltimore, Baltimore, Maryland
`
`Selection and Program Committee, University of Maryland,
`Baltimore, Maryland (NHLBI sponsored Short-term Research
`Training for Minority Students Program
`
`Associate Dean Search Committee, University of Maryland
`School of Medicine, Baltimore, Maryland
`
`House Staff Selection Committee, Department or Medicine,
`Duke University Medical Center
`
`Cardiopulmonary Resuscitation Committee, Duke University
`Medical Center
`
`Emergency Room Advisory Committee, Duke University
`Medical Center
`
`UNITED THERAPEUTICS, EX. 2023
`WATSON LABORATORIES V. UNITED THERAPEUTICS, |PR2017—D1621
`Page 7 of 62
`
`

`

`I982
`
`I982
`
`I983
`
`I984
`
`I985
`
`I986
`
`1986—1988
`
`1987
`
`NHLBI ad hoc study section For Primary Pulmonary
`I-lypeltension, National Data and Coordinating Center
`Contracts
`
`Planning Committee for NHLB] Primary Pulmonary
`llypertension Multicenter Study
`
`Participating Investigator, NHLBI Cooperative Study of
`Primary Pulmonary Hypertension
`
`Alfred Richman Competition Review Committee, American
`College of Chest Physicians
`
`Planning Committee for NHLBI, Pulmonary Vascular
`Diseases and Respiratory Failure Programs
`
`Research and Development Committee, Dallas VA. Medical
`Center
`
`Site Visit Committee, Pulmonary SCOR Application Division
`of Lung Diseases, NHLBI, NIII for Yale University, New
`Haven, Connecticut
`
`Executive Committee on Pulmonary Circulation, American
`Thoracic Society
`
`Medical School Admissions Committee, University ofTexas
`Health Science Center Southwestern Medical School, Dallas,
`Texas
`
`Publications Committee, NHLBI, Registry for Primary
`Pulmonary Ilypcrtcnsion
`
`Secretary, Pulmonary Circulation Section, American Thoracic
`Society
`
`Chairman Elect, Pulmonary Circulation Section, American
`Thoracic Society Site Visit Committee, Cystic Fibrosis
`Foundation, for Johns Hopkins University Grant Application
`
`Member at Large, Executive Committee, Cardiopulmonary
`Council, American Heart Association
`
`Executive Committee, Maryland Thoracic Society
`
`Chairman, Pulmonary Circulation Section, American Thoracic
`Society
`
`UNITED THERAPEUTICS, EX. 2023
`WATSON LABORATORIES V. UNITED THERAPEUTICS, |PR2017—D1621
`Page 8 of 62
`
`

`

`I988
`
`I939
`
`I939
`
`I99l
`
`1991—1993
`
`l99l—I995
`
`1991—1994
`
`I992
`
`I992— I997
`
`I992 — Present
`
`I992 — I993
`
`I993 — I995
`
`I993 , 1996
`
`1994
`
`Program Committee. American College oI‘Chcst Physicians
`Original Investigations Committee, American College of
`Chest Physicians
`
`Program Committee, Cardiopulmonary Council, American
`Heart Association
`
`Board of Governors, American College oi'Chest Physicians
`
`President-Elect, Maryland Thoracic Society
`
`Research Review Committee, American Heart Association,
`Maryland Affiliate
`
`National Heart, Lung, and Blood Institute, A'I‘S Lung
`Transplantation Committee
`
`President, Maryland Thoracic Society
`
`Board ot‘Directors and Executive Committee, American Lung
`Association of Maryland Study Section, University of
`California Tobacco-Related Disease Program
`
`Program Specialist in Respiratory and Pulmonary Disease,
`Department ofVcterans Affairs, Washington, I).C.
`
`Research Progress and Initiatives Committee, National Heart,
`Lung and Blood Institute National Institutes of Health
`
`Chairman, American College ofChest Physicians Consensus
`Panel on Primary Pulmonary Hypertension
`
`Executive Committee oflhe Council on Cardiopulmonary and
`Critical Care, American Heart Association
`
`Scientific Advisory Board, United Patients Association for
`Pulmonary Hypertension
`
`Oversight Committee Pulmonary SCOR Program, National
`Heart, Lung, and Blood Institute, National Institutes ofllealth
`
`President, American Lung Association of Maryland
`
`Scientific Sessions Committee, American Ileart Association
`
`National Institutes ofllealth, National Heart, Lung, and Blood
`Institute, Program Project Committee
`
`UNITED THERAPEUTICS, EX. 2023
`WATSON LABORATORIES V. UNITED THERAPEUTICS, |PR2017—D1621
`Page 9 of 62
`
`

`

`1998
`
`1998
`
`1999
`
`2000 — 2002
`
`2001 —
`
`2002
`
`2002 — 2004
`
`2002 —
`
`2003 —
`
`2005 —
`
`2006 -~
`
`2008 ,
`
`Chair, Working Group on Pulmonary Vascular Diseases,
`American Heart Association
`
`Co-Chair, World Health Organization Conference on Primary
`Pulmonary Hypertension
`European Society of Cardiology Task Force on Pulmonary
`Hypertension
`
`Scientific Advisory Committee ol'the University of California
`'l‘obacco-Related Disease Research ngram (TRDRP)
`
`Chair, Research Committee, Pulmonary Hypertension
`Association
`
`Special Emphasis Panel, NHLBI Mentored Scientist
`Development Award Program
`
`Chair, ACCP Evidence-Based Clinical Practice Guideline
`Consensus Panel on Pulmonary Artery Hypertension
`
`Member, Medical Advisory Board, Scleroderma Foundation
`
`Member, Organizing Committee, 31" WHO Conference on
`Pulmonary Hypertension
`
`Chairman, Data Monitoring Committee, Sildenafil for
`Pediatric Pulmonary Hypertension Program, Pfizer Inc.
`
`Chairman, Data Monitoring Committee, Bosentan in addition
`to Sildenafil in Pulmonary Hypertension Program, Actelion
`Pharmaceuticals.
`
`European Society of Cardiology Task Force Meeting on the
`Diagnosis & Treatment of Pulmonary Arterial Hypertension
`(Update)
`
`American College ofCardiologyI/tmcrican Heart Association
`
`Clinical Expert Consensus Document (CECD) Writing Group
`on Pulmonary Hypertension
`
`Special Emphasis Committee, NI iLBI, Respiratory Integrative
`Biology and Translational Research {RIB'I‘) Study Section {4—
`6 Feb, Washington DC)
`
`Co-Chairman, Steering Committee, 4th World Symposium on
`PAH, Dana Point, CA, 1 1-14 Feb 2008
`
`Presenter on behalfofNational Pulmonary Hypertension
`
`10
`
`UNITED THERAPEUTICS, EX. 2023
`WATSON LABORATORIES V. UNITED THERAPEUTICS, |PR2017—D1621
`Page 10 of 62
`
`

`

`2008 —
`
`Centers of UK Physicians Committee Stakehoiders to National
`Institute of Clinical [Excellence (NICE), Westminster, London,
`24 June
`
`Joint European Society of Cardiology (ESC) and European
`Respiratory Society (HRS) Task Force Meeting on the
`Diagnosis and Treatment of Pulmonary Arterial Hypertension
`(Update)
`
`Data Safety Monitoring Board, Clinical Trials in Pulmonary
`Diseases with HIV Infections, NI-IIBI, N111
`
`Organizing Committee, 4'“ World Symposium on Pulmonary
`Hypertension
`
`NHLBI Review Section, Scientific Conferences
`
`Steering Committee, 5‘" World Symthsium on Pulmonary
`Hypertension
`
`Chair, Site Visit and Grant Review Committee for expert
`evaluation ofthc Ludwig Boltzmann Institute for Lung
`Vascular Research (LBl-IJVR), Vienna, Austria
`
`Chair, Site Visit and Grant Review Committee for expert
`evaluation ofthe Ludwig Boltzmann Institute for Lung
`Vascular Research (IJBI-LVR), Vienna, Austria
`
`201 I —
`
`2012 —
`
`2012 — 2013
`
`2013 — 20 I4
`
`2016 — 201?
`
`TEACHING ACTIVITIES:
`
`I986 — 1992 Section Director: Respiration Physiology Section (170 students)
`I986 — 1995 Medical Physiology Course {MBPH 501, MBPII 601) (150 students)
`1996 — 1998 ReSpiration Pathology Course {1'10 students)
`1999
`Respiration Physiology (170 students)
`2004
`Introduction to Clinical Medicine, Observed Structured Clinical Examination
`Course (10 students)
`
`MEDICAL VOLUNTEER ACTIVITIES:
`
`July — Aug 2008
`
`Medical Volunteer, Pacific Partnership, USNS Mercy
`Timor Leste, Southeast Asia
`
`May 2009 —
`
`Medical Volunteer, UCSI) Free Clinic Project
`Southeast San Diego, CA
`
`August 2012 —
`
`Medical Volunteer, Comfort the Children (C'I'C) International
`Maai Mahiu, Kenya, Africa
`
`Il
`
`UNITED THERAPEUTICS, EX. 2023
`WATSON LABORATORIES V. UNITED THERAPEUTICS, |PR2017—D1621
`Page 11 of 62
`
`

`

`PATENTS:
`
`#7,064,573
`
`#8,609,728
`
`#8,969,409
`
`#9,339,507
`
`#9,358,240
`
`Regulating expression of transient receptor potential channel genes.
`The
`present
`invention
`relates
`to
`compositions
`related
`to
`a
`polymlcleotide encoding a transient receptor potential channel gene.
`Also disclosed is
`the use of this polynuclcotide,
`its homologs,
`fragments, variants and its resultant polypeptides in the diagnosis,
`prevention
`and
`treatment of disease,
`particularly
`idiopathic
`pulmonary arterial hypertension (IPAII). This invention also teaches
`the use of these polynucleolides and polypeptides as assays for drug
`discovery and therapies. Issued USP'I‘O 6f21fl 1
`
`Treatment for pulmonary hypertension. A method oftreating
`pulmonary hypertension based upon eo-adminislering to a subject in
`need thereofa pharmaceutically effective amount of an oral
`therapeutic agent for treating pulmonary hypertension and a
`pharmaceutically effective amount ofan inhaled therapeutic agent for
`treating pulmonary hypertension. Issued USPTO 12117143
`
`Treatment for pulmonary hypertension. A method of treating
`pulmonary hypertension comprising co-administering to a subject in
`need thereofa pharmaceutically effective amount of an oral
`therapeutic agent for treating pulmonary hypertension and a
`pharmaceutically effective amount of an inhaled therapeutic agent for
`treating pulmonary hypertension, wherein the oral therapeutic agent is
`beraprost or a pharmaceutically acceptable salt thereofadministered
`orally and the inhaled therapeutic agent is treprostinil or a
`pharmaceutically acceptable salt thereofadministered by inhalation.
`Issued USP'I‘O 031'03115
`
`Treprostinil administration by inhalation. Treprostinil can be
`administered using a metered dose inhaler. Such administration
`provides a greater degree of autonomy to patients. Also disclosed are
`kits that include a metered dose inhaler containing a pharmaceutical
`formulation containing treprostinil. Issued USP'I‘O 5f] ”#16
`
`Trcprostinil administration by inhalation. 'I'reprostinil can be
`administered using a metered dose inhaler. Such administration
`provides a greater degree ofautonomy to patients. Also disclosed are
`kits that include a metered dose inhaler containing a pharmaceutical
`formulation containing trcprostinil. Issued USPTO 6.1071” 6
`
`[2
`
`UNITED THERAPEUTICS, EX. 2023
`WATSON LABORATORIES V. UNITED THERAPEUTICS, |PR2017—D1621
`Page 12 of 62
`
`

`

`GRANT SUPPORT:
`
`I979 - 1980
`
`1980—1982
`
`1980 H 1935
`
`01181—12/81
`
`[981—1932
`
`12/81—11i‘84
`
`1981—1985
`
`1982—1985
`
`1983—1934
`
`1983-1984
`
`i984—1987
`
`1984—1986
`
`1984—1986
`
`American Lung Association of'North Carolina: "Vasodilators in Pulmonary
`Hypertension,” $2,500, L.J. Rubin, Principal Investigator.
`
`American Lung Association: “The Effects of‘Vasodilator-s in Experimental
`Pulmonary Hypertension," $30,000, L.J. Rubin, Principal Investigator.
`
`Burroughs Welcome Company: “Prostaeyclin (P012) as Pulmonary Vasodilator in
`Pulmonary Hypertension,” $I5,000, L.J. Rubin and BM. Groves, Co-lnvestigators.
`
`National institutes of Health, Biomedical Research Fund (through the University of
`Texas Health Science Center): “Prostaglandins as Modulators of Pulmonary
`Vascular Tone,” $4,000, L.J. Rubin. Principal Investigator.
`
`Veterans Administration: “Role of Prostaglandins as Mediators of I lypoxic
`Vasculature,” $25,000, L.J. Rubin, Principal Investigator.
`
`National Heart, Lung, Blood Institute, NIII: “Prostaglandin Modulation of
`Pulmonary Vascular Tone,” $82,579 (total award), L.J. Rubin, Principal
`Investigator.
`
`Division of Research Resources, NIH: “Hemodynamie and Gas Exchange Effects of
`Therapy for Primary and Secondary Pulmonary Arterial Hypertension.” L.J. Rubin,
`Principal Investigator, through the General Clinical Research Center Program,
`University ofTexas Health Science Center at Dallas.
`
`Betty Crossman Marcus Memorial Fund for Pulmonary Research, through the
`University ofTexas Health Science Center. $75,000, L.J. Rubin, Principal
`Investigator.
`
`Miles Institute for Preclinical Research: “The effects of Nafazatron on Hypoxic
`Pulmonary Vasoconstriction in Dogs,” $4,000, L.J. Rubin, Principai Investigator.
`
`Miles Laboratories: “The Effects of Nitrcndipine in Patients with Primary and
`Secondary Pulmonary Hypertension,” $27,500, Lewis .I. Rubin, Principal
`Investigator.
`
`Veterans Administration Research Service (Merit Review): “Mechanisms of
`Pulmonary Vascular Reactivity in Chronic Lung Disease,” $1 19,800, L.J. Rubin,
`Principal Investigator.
`
`Burroughs Welcome Company: “The Ilemodynamic and Gas Exchange Effects at
`Rest and During Exercise ofProstacycIin (PGI2) and 13W in Patients with Chronic
`Cor Pulmonale,” $45,000, L.J. Rubin, Principal Investigator.
`
`American Edwards Laboratories: “Measurement of Right Ventricular Ejection
`Fraction (RVEF) Using Thermodilution Technique and Correlation Between RVEF
`and Pulmonary I-Iemodynamics in Patients with or Pulmonale,” $5,000, L.J. Rubin,
`Principal Investigator.
`
`13
`
`UNITED THERAPEUTICS, EX. 2023
`WATSON LABORATORIES V. UNITED THERAPEUTICS, |PR2017—D1621
`Page 13 of 62
`
`

`

`1935—1989
`
`I986 —- I989
`
`I987 — I990
`
`I990 — I993
`
`Miles Pharmaceuticals: "Nitrcndipine Vs. Placebo in Pulmonary Hypertension
`Secondary to Chronic Obstructive Lung Disease,” $65,000. LJ. Rubin, Principal
`Investigator.
`
`Institute for Preclinical Pharmacology, Miles Laboratories: “Effects ofCalcium
`Channel Blockade on Pathogenesis ol'Cor Pulmonale in Papain«lnduecd
`Emphysema in Dogs," $l0,000, l.J Rubin, MD, Principal Investigator.
`
`Veterans Administration Research Service (Merit Review): “Superoxidc~Mediated
`Pulmonary Vascular Reactivity," $540,500, G. Rosen & I,.J. Rubin, Principal
`Investigators.
`
`Veterans Administration Research Service (Merit Review): “Pathogenesis of
`Pulmonary Hypertension in Emphysema," $324,900, LJ. Rubin, Principal
`Investigator.
`
`I993 — I998
`
`NIH: NHLBI Vascular Disease Academic Award, Direct cost: $517,614, Indirect
`
`m: $4l,409, I..I Rubin, MD, Principal Investigator.
`
`1994 — I997
`
`1996
`
`1996 — 199?
`
`I996 — I998
`
`I998 -— 2002
`
`I997 — I998
`
`I999 — 2003
`
`2006
`
`Parker B. Francis Fellowship Program: Role oflon Channels in Hypoxic Pulmonary
`Vasoconstriction,” Xiao-Iian Yuan, MD, PhD., Principal Investigator, L..I. Rubin,
`MD, Sponsor
`
`Primary Pulmonary Hypertension Cure Foundation: K+ Channel Structure and
`Function in PPH. Direct cost: $3I6,642, Indirect cost: $100,000, LJ. Rubin, MD,
`Principal Investigator, X-J Yuan, MD, PhD, Principal Investigator.
`
`Primary Pulmonary Hypertension Research Foundation: Ion Channels in Primary
`Pulmonary Hypertension. $50,000, LJ. Rubin, Principal Investigator, JX-J Yuan,
`Co-Investigator.
`
`Glaxo Welcome: Flolan in Pulmonary Hypertension Secondary to Scleroderma.
`Direct cost: $400,000, Indirect cost: $66,667, Lewis .I. Rubin, M.D., Principal
`Investigator.
`
`Harvard School of Public Health: Study of Pulmonary Hypertension in America.
`Direct cost: $400,000, Lewis J. Rubin, MD, Principal investigator.
`
`United Therapeutics: A Dose Range-Finding Study of Intravenous ISAUSI in
`Patients with Primary Pulmonary Hypertension. Direct cost: $36,800, Indirect cost:
`$7360, Lewis J. Rubin, MD, Principal Investigator.
`
`NIH: Cellular Mechanisms of PPI 1: Role of K+ Channels. (ROI HL64945-01).
`Direct cost: $90|,753, Indirect cost: $453,029 Lewis J. Rubin, MD, Co-Investigator.
`
`NIH: Pulmonary Vascular Responses in Primary Pulmonary Hypertension. NI—ILBI
`Pharmacogenomies Research Centers. Direct cost: $775,346, Indirect cost:
`$399,303, Lewis J. Rubin, MD, Co-lnvestigator.
`
`14
`
`UNITED THERAPEUTICS, EX. 2023
`WATSON LABORATORIES V. UNITED THERAPEUTICS, |PR2017—01621
`Page 14 of 62
`
`

`

`2006
`
`NIH: Capacitative Ca2+ Entry in Pulmonary Myocyte Growth. (I R01 HL660I2-
`OIAI). Direct cost: $1,250,000, Indirect Cost: $650,000. Lewis J. Rubin, MD, Co-
`Investigator.
`
`2002 — 2005 NIH: Autonomic Pharmacodynamic Pharmacogenomics—Pulmonary Vascular
`Responses in PPH. (5U01HL69758-02). Lewis J. Rubin, MD, Principal Investigator
`on Project 1.
`
`2003 — 2007 NIH: Cellular Mechanisms ofPPH: Role of Potassium Channels (SROI HL 64945-
`
`08). Lewis J. Rubin, MD, Clo-Investigator
`
`2005 — 2007 NIH: SNPs in IdiOpathic Pulmonary Arterial Hypertension (IRZI HL 80033-02).
`Lewis J. Rubin, MD, (Jo-Investigator
`
`2001 — 2012 NIH: Capacitative Ca2+ Entry and TRP Channels in Thromboembolic Pulmonary
`Hypertension. (SROI HL066012-07). Lewis J. Rubin, MD, Co-Investigator.
`
`l5
`
`UNITED THERAPEUTICS, EX. 2023
`WATSON LABORATORIES V. UNITED THERAPEUTICS, |PR2017—D1621
`Page 15 of 62
`
`

`

`Books
`
`Pulmonary Heart Disease, 1.] Rubin, editor, 1984. Martinus Nijhoff, Boston, MA.
`
`Primary Pulmonary Hypertension, M Rubin and SR Rich, editors, 1996. Marcel Dekker,
`NY, NY.
`
`Pulmonary Circulation, A] Peacock and LJ Rubin, editors, 2004. Edward Arnold
`Publisherlexford University Press, London, UK.
`
`The Endorhelin System in Cardiopulmonary Diseases, M Clozel and LJ Rubin, editors,
`2004. Rheinhard Druek Publishers, Basel, Switzerland.
`
`Pulmonary Arterial Hypertension Related to Congenital Heart Disease, M Beghetti, RJ
`Burst, R Naeijc, and 1.] Rubin, editors, 2006, Elsevier Publishers, Munich, Germany.
`
`Pulmonary Circulation: DiseaSes and Their Trearmem, 3rd edition, A] Peacock, R Naeije,
`and LJ Rubin, editors. Hodder Arnold, 2011, London, UK.
`
`Pulmonary Circulation: Diseases and Their Treatment, 4th Edition, AJ Peacock, R Nacije,
`L] Rubin, editors. CRC Press, 2016, London UK.
`
`Monographs
`
`. Konstam MA, Draeup K, Baker DW, Bottorli MB, Brooks NH, Dacey RA, Dunbar SB,
`Jackson AB, Jessup M, Johnson JC, Jones RH, Luehi RJ, Massie BM, Pitt B, Rose EA, Rubin
`Q, Wright RF, Hadorn DC: Heart Failure: Evaluation and Care of Patients with Left
`Ventricular Dysfunction. Clinical Practice Guideline Number 11, AHCPR Publication No.
`94—0612, U.S. Department of Health and Human Services, Rockville, Maryland, June 1994.
`
`. Rubin LJ, editor: Proceedings of the Brcnot Symposium on the Pathogenesis of Pulmonary
`Hypertension. Chest (Suppl) 1998, Vol. 114 (3): 1838-2478.
`
`
`. Rubin Ll guest editor: Pulmonary Vascular Diseases. Progress in Cardiovascular Diseases
`2002; 45 (2).
`
`editors: Pulmonary Arterial Hypertension: Epidemiology,
`. Galie N, Rubin LJ, guest
`Pathohiology, Assessment, and Therapy. JAmer Coll Cardiol 2004 (supplement); 43 (12): IS-
`908.
`
`. Rubin LJ, editor: Diagnosis and Management of Pulmonary Arterial Hypertension: ACCP
`Evidence-Based Clinical Practice Guidelines. Chest 2004 (supplement); 126(1) 18-928.
`
`
`Rubin Ll Hoeper MM, Simonneau G, editors: Pathogenesis and Treatment of Chronic
`Thromboembolic Pulmonary Hypertension. Proc Amer Thoracic Society, 2006; 3: 563-6 I 6.
`
`10
`
`UNITED THERAPEUTICS, EX. 2023
`WATSON LABORATORIES V. UNITED THERAPEUTICS, |PR2017—D1621
`Page 16 of 62
`
`

`

`Peer Review Manuscripts:
`
`Articles
`
`l.
`
`2.
`
`3.
`
`4.
`
`5.
`
`6.
`
`7.
`
`3.
`
`9.
`
`10.
`
`ll.
`
`12.
`
`[3.
`
`14.
`
`Rubin IJ, Gutman RA: llypotension during hemodialysis. Kidney I973; 11:21-26.
`
`Rubin l.J, Peter Rl-l: Oral hydralazine therapy for primary pulmonary hypertension. N Engir
`JMeri I980; 302:69-73.
`
`Rubin LJ, Peter RH: Primary pulmonary hypertension new approaches to therapy. Am
`HenrtJ [980; 100:757-759.
`
`Rubin LJ, Peter RH: Rest and exercise hernodynamic effects of oral hydralazine in patients
`with cor pulmonale. Am J Cnrriioi 198] ; 4?:1 l6—l22.
`
`Influence of prostaglandin synthesis inhibitors on the pulmonary
`Rubin lJ, Lazar JD:
`vasodilator effects of hydralazine in dogs with hypoxic pulmonary vasoconstriction. J Ciin
`Invest 1953!; 67:193-200.
`
`Rubin LJ, Handel F, Peter RH: The effects of oral hydralazine on right ventricular end
`diastolic pressure in patients with right ventricular failure. Circulation 1982; 65: 1369-1373.
`
`Rubin Ll, Groves BM, Reeves JT, Frosolono MF, Handel F, Cato AE: Prostacyclin-induced
`acute pulmonary vasodilation in primary ‘ pulmonary hypertension. Circulation 1982;
`66:334-33 8.
`
`Cohen MD, Rubin L], Taylor WE, Cuthbert JA: Primary pulmonary hypertension A unique
`case associated with extrahepatie portal hypertension. Hepntniogy 1983; 3:588-592.
`
`Rubin LJ, Lazar JD: Nonadrcnergic effects ofisoproterenol in dogs with hypoxic pulmonary
`vasoconstriction: Possible role of prostaglandins. J Ciin Invest 1983; 71:]366-1374.
`
`Chappell 'I‘R, Rubin L], Markham RV, Firth BG: Independence of oxygen consumption and
`systemic oxygen transport
`in patients with either stable pulmonary hypertension or
`refractory lefi ventricular failure. Am Rev Respir Dis I983; l28:30-33.
`
`Henrich WL, Woodard TD, Meyer BI), Chappell TR, Rubin LJ: High sodium bicarbonate
`and acetate hemodialysis: A doubleblind crossover comparison of hemodynamic and
`ventilatory effects. Kidney Inter 1983; 24:245-250.
`
`Rubin LJ, Nicod P, Hillis LD, Firth BG: Treatment of primary pulmonary hypertension with
`nif‘edipine: A hemodynamic and scintigraphic evaluatiOn. Ann int Med I983; 99:433-438.
`
`Miller MJ, Chappcll TR, Cook W, Deolazabol JR, Rubin LJ: The effects oforal hydralazinc
`on gas exchange in patients with cor pulmonale. Am JMed I983; 75:937-942.
`
`llunt .lM, Chappell 'I'R, llenrich WL, Rubin LJ: Gas exchange during dialysis: Contrasting
`mechanisms for the alterations with acetate and bicarbonate buffers. Ant J Med 1984;
`77:255-260.
`
`[7
`
`UNITED THERAPEUTICS, EX. 2023
`WATSON LABORATORIES V. UNITED THERAPEUTICS, IPR2017—D1621
`Page 17 of 62
`
`

`

`15.
`
`I6.
`
`1?.
`
`18.
`
`19.
`
`20.
`
`2[.
`
`22.
`
`23.
`
`24.
`
`25.
`
`26.
`
`27.
`
`28.
`
`Hughes JD, Rubin L]: The relationship between mixed oxygen venous tension and
`pulmonary vascular tone in dogs during normoxic, hypcroxic, and hypoxic ventilation. Am
`J Cordial 1984; 54:402-409.
`
`linsley RD, Rubin 1,]: Nafazatrom (Bay g 6575) blunts canine hypoxie pulmonary
`vasoconstriction:Evidence
`for
`a prostaglandinmediatcd mechanism. Prosmglemims,
`Leukot‘rrenes rmdMeo‘r‘eine I985; [8:95-104.
`
`Groves BM, Rubin IJ, Reeves JT, Frosolono MF: Comparable hemodynatnie effects of
`prostacyclin and hydralazine in primary pulmonary hypertension. Am Heart J I985;
`l l0:l200-l204.
`
`Rubin LJ, llughes JD, Lazar JD: The effects ofeicosanoid synthesis inhibitors on normoxic
`and hypoxie pulmonary vascular tone in dogs. Am Rev Respir Dr's 1985; {32:93-98.
`
`Rubin LJ: Diagnosis and management of pulmonary thromboembolism. Am J Med SciF
`1985; 290167-177.
`
`Brophy MH, Kiser SR, Rubin LJ: Nonsuppression of ACTH in Lung Cancer. Biol
`Psychiatry 1985; 20:584-5 85.
`
`Hughes JD, Rubin LJ: Primary pulmonary hypertension—An analysis of 28 cases and a
`review ofthe literature. Medicine 1986; 65:56-72
`
`Rubin LJ, Moser KF: Longtcrm effects of nitrendipine on hemodynamics and oxygen
`transport in patients with cor pulmonale. Chest 1986; 89:141-145.
`
`Dal Nogare AR, Rubin L]: The effects of hydralazine on exercise capacity in pulmonary
`hypertension secondary to chronic obstructive pulmonary disease. Am Rev Renoir Dis 1986;
`133:385-389.
`
`Pei] ML, Rubin 1,]: Effects of oxygen therapy titrated to raise mix